TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3813145
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine 0.375% without glucose (Group I)
Study: 3813145
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine 0.375% with 2.5% glucose (Group II)
Study: 3813145
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine 0.375% with 7.5% glucose (Group III)
Study: 24344872
Drug: T/iDHT/E2 (Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/iDHT/E2 (Testosterone gel with dutasteride)
Study: 24344872
Drug: T/DHT/E2 (Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/DHT/E2 (Testosterone gel alone)
Study: 24344872
Drug: T/DHT/iE2 (Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/DHT/iE2 (Testosterone gel with anastrazole)
Study: 21503628
Drug: Forest therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forest therapy camp program
Study: 21503628
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily routines (Control)
Study: 20110084
Drug: duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine (60 mg/day)
Study: 16249960
Drug: Citicoline (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1,000 mg/die intramuscularly) for 2 months
Study: 16249960
Drug: Citicoline (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1,000 mg/die intramuscularly) during additional 2-month periods for a total of 16 periods in 8 years
Study: 12132610
Drug: Zinc picolinate
Normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc picolinate (29 mg orally by capsule 3 times a day for 3 months)
Study: 10745565
Drug: AngioJet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AngioJet therapy
Study: 2082492
Drug: Dipyridamole (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (oral and intravenous)
Study: 7006663
Drug: Good renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good renal function with haemoglobin above 100 g/l
Study: 30012187
Drug: Intraoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV)
Study: 30012187
Drug: Placebo: routinely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: routinely used intraocular infusion with balanced salt solution during routine PPV
Study: 17442998
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/d) with cisplatin and gemcitabine
Study: 8607400
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (600 mg/day, orally for 14 days)
Study: 7165010
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 5.5 gm/m2 daily for 30 days
Study: 23386016
Drug: Computer‐Assisted Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer‐Assisted Insulin Protocol
Study: 20457167
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg single oral dose of propranolol (beta-noradrenergic antagonist)
Study: 15710304
Drug: Formal Elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal Elements Art Therapy Scale task
Study: 11845369
Drug: Active (Ga-As)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active (Ga-As) laser treatment
Study: 7623991
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEi) - 10 mg enalapril o.d.
Study: 7623991
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LPD and ACEi
Study: 31465842
Drug: Membrane-active antiarrhythmic
Normalized name: Factive
DrugBank: Gemifloxacin (DB01155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Membrane-active antiarrhythmic drugs
Study: 31465842
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulation with non-vitamin K-antagonist oral anticoagulants
Study: 30910488
Drug: Noninvasive interactive
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive interactive neurostimulation (NIN) therapy
Study: 25824327
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab (anti-VEGF drugs) administered as needed over a 2-year period.
Study: 21091083
Drug: FOX (Fitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOX (Fitting to Outcomes eXpert) software tool for programming cochlear implant processors
Study: 15542165
Drug: WF10 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WF10 therapy (0.5 ml/kg body weight, diluted in physiological saline or 5% dextrose water, intravenous infusions over 2 h on 5 consecutive days, every 3 weeks for 2 cycles)
Study: 11103099
Drug: ipriflavone-containing supplement
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipriflavone-containing supplement
Study: 23803591
Drug: Bisoprolol/hydrochlorothiazide 5/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol/hydrochlorothiazide 5/6.25 mg (n=89; R)
Study: 23803591
Drug: Amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/160 mg (n=94; E)
Study: 19572934
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) regional caffeine at 10 mg/kg
Study: 19572934
Drug: Systemic caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic caffeine at 10 mg/kg
Study: 15497669
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan tablets (Sarvas)
Study: 15497669
Drug: losartan/hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/hydrochlorothiazide (50 mg/12.5 mg) (Sarvastan)
Study: 8164026
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin applied to half of the back for 6 months
Study: 2452563
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 mg rscu-PA bolus followed by 60 mg infusion over 1 hour
Study: 2452563
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 10 mg rscu-PA bolus followed by 30 mg infusion
Study: 2452563
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 80 mg rscu-PA
Study: 29739454
Drug: 1.5% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% L-menthol application
Study: 21600759
Drug: Temozolomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (150 mg/m²/day for 7 days every 2 weeks)
Study: 21600759
Drug: Dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1000 mg/m²/day on day 1 every 3 weeks)
Study: 17875806
Drug: Single autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide (100 mg per day during 6 months) (arm B)
Study: 16421420
Drug: Temozolomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (150 mg/m2 for 7 days every other week) and Thalidomide (50 to 400 mg daily)
Study: 1362556
Drug: Suriclone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.4 mg tid (young)
Study: 1362556
Drug: Suriclone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.1 mg and 0.2 mg tid (elderly)
Study: 3104448
Drug: New micro‐encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New micro‐encapsulated formulation
Study: 3104448
Drug: All 5
Normalized name: Levall 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 5 preparations
Study: 28585182
Drug: Lime powder
Normalized name: Lime
DrugBank: Lime (citrus) (DB10635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lime powder (LP) treatment for 6 months
Study: 16365061
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g FOS
Study: 11299572
Drug: Larval debridement
Normalized name: Bombyx mori larva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval debridement therapy (LDT)
Study: 9058684
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 0.56 mg per day
Study: 9058684
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 0.28 mg per day
Study: 8364018
Drug: Indobufen 50
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 50 mg BID
Study: 8364018
Drug: Indobufen 100
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 100 mg BID
Study: 8364018
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg BID
Study: 3539127
Drug: lonazolac 300
Normalized name: lonazolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonazolac 300 mg b.i.d.
Study: 3539127
Drug: indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 75 mg b.i.d.
Study: 24749843
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil cream
Study: 23355301
Drug: Rolofylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolofylline (1 to 60 mg, infused over 1-2 hours)
Study: 12789232
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (2-week course)
Study: 10523461
Drug: Particular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particular therapy
Study: 8821611
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds)
Study: 8821611
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy A (triple therapy+omeprazole 20 mg od)
Study: 8821611
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy B (triple therapy+omeprazole 40 mg od)
Study: 7152081
Drug: 0.05% diflorasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% diflorasone diacetate ointment applied once daily
Study: 7152081
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate ointment applied twice daily
Study: 26026604
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) treatment
Study: 24338461
Drug: Intraarticular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular steroid injection
Study: 20538138
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of Lp(a) distribution (>/=32.9 mg/dl)
Study: 20538138
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of Lp(a) distribution (<32.9 mg/dl)
Study: 16368299
Drug: Tomato extract,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato extract, 250 mg Lyc-O-Mato, during an 8-week treatment period
Study: 9368236
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (200 mg/day for 6 months)
Study: 9368236
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without magnesium supplementation (control group)
Study: 1544017
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of antidepressant medication at night
Study: 1544017
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of medication during the day
Study: 3929553
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl (50 micrograms/kg)
Study: 30326883
Drug: iMOVE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: iMOVE therapy
Study: 27721227
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen supplementation (2 L/min to 3 L/min) with standard hydration (n = 176)
Study: 18325675
Drug: Augmented Reality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Reality (AR) as an adjunct to analgesia and sedation
Study: 18325675
Drug: Basic cognitive
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic cognitive therapy (Control)
Study: 12925455
Drug: Pexelizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab 2.0 mg/kg bolus
Study: 12925455
Drug: Pexelizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab 2.0 mg/kg bolus plus 0.05 mg/kg per h for 20 hours
Study: 10800064
Drug: Neoral (cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (cyclosporin A) at twice the last i.v. dose
Study: 10800064
Drug: Neoral (cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (cyclosporin A) at the same last i.v. dose
Study: 8717398
Drug: Hybrid vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid vaccine combining outer membrane protein F (OprF) and outer membrane protein I (OprI)
Study: 8717398
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with recombinant OprI expressing Salmonella dublin
Study: 1449918
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg three times daily for 28 days
Study: 1449918
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 20 mg three times daily for 28 days
Study: 6727272
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20 mg diltiazem hydrochloride
Study: 6727272
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 120 mg diltiazem in solution form
Study: 6727272
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 120 mg diltiazem as two 60-mg sustained-release tablets
Study: 22229256
Drug: Oral letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral letrozole (2.5 mg/day)
Study: 21975350
Drug: Oral exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral exemestane (25 mg/day)
Study: 18304286
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg taken on demand for up to 12 weeks
Study: 17000812
Drug: Standard combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined spinal epidural (Std CSE) with hyperbaric bupivacaine 10 mg and intrathecal fentanyl 15 microg
Study: 17000812
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined spinal epidural (Seq CSE) with hyperbaric bupivacaine 5 mg and intrathecal fentanyl 15 microg
Study: 25670917
Drug: Remifentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (2 μg.kg(‐1) bolus, 2‐7 μg.kg(‐1).min(‐1) infusion)
Study: 25670917
Drug: High-dose sufentanil-sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sufentanil-sevoflurane (control group)
Study: 25119853
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol supplementation (9 g kg(‐1)) with rapeseed meal (RSM)
Study: 25119853
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol supplementation (9 g kg(‐1)) with cottonseed meal (CSM)
Study: 19262229
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (30 mg/day)
Study: 17852947
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of amphotericin B deoxycholate (1 mg/kg)
Study: 17852947
Drug: Alternate-day administration
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day administration of amphotericin B deoxycholate (2 mg/kg)
Study: 9522109
Drug: Nabumetone 2000
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone 2000 mg daily
Study: 2390432
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg three times daily and cholestyramine 4 g three times daily
Study: 2390432
Drug: Acipimox added
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox added to cholestyramine therapy
Study: 7409937
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pentobarbital
Study: 30650260
Drug: ELX-02 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELX-02 (0.3 mg/kg to 7.5 mg/kg)
Study: 23592830
Drug: EFV (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV (600 mg) on-RIF
Study: 23592830
Drug: EFV (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV (600 mg) off-RIF
Study: 17078771
Drug: Fasting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting therapy (FT) consisting of 10 days of starvation followed by 5 days of refeeding
Study: 17078771
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (basic treatment consisting of pharmacotherapy and brief psychotherapy)
Study: 31906748
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) - a single individualized session along with a recorder and journal for home use
Study: 31906748
Drug: Music Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Plus - weekly group MT sessions along with a recorder and journal for home use
Study: 30919549
Drug: Biomarker-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided treatment strategy
Study: 28654556
Drug: Sufentanil 100
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 100 μg + dexmedetomidine 200 μg + normal saline 100 mL (group D)
Study: 28654556
Drug: Sufentanil 100
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 100 μg + normal saline 100 mL (group C)
Study: 25526455
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for older patients with stage II disease
Study: 25526455
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for older patients with stage III disease
Study: 25526455
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for older patients with colon cancer
Study: 25526455
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for older patients with rectal cancer
Study: 25526455
Drug: Preoperative short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative short-course radiotherapy for older patients with stage III rectal cancer
Study: 25526455
Drug: Preoperative short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative short-course radiotherapy for older patients with rectal cancer
Study: 25526455
Drug: Surgery for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery for rectal cancer patients aged ≥80 years
Study: 21972424
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg daily for three months
Study: 21972424
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily for three months (after atorvastatin)
Study: 21972424
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily for three months (after placebo)
Study: 15939064
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 mg), Vitamin B6 (25 mg), Vitamin B12 (0.5 mg)
Study: 1955196
Drug: Troleandomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troleandomycin (1 g bid over a 10‐day period)
Study: 1955196
Drug: Josamycin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (same doses as T)
Study: 25424602
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (RO) diet (14-27 g/day) for 13 weeks
Study: 25424602
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (SO) diet (14-27 g/day) for 13 weeks
Study: 23172400
Drug: Prescription-oriented (Pr‐O)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription-oriented (Pr‐O) approach
Study: 17530483
Drug: Thalidomide alone
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide alone (200 mg/day up to 800 mg/day)
Study: 15005733
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) only (n=16)